PMKB
PMKB
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity
Login
BRAF
Information
View History
Pending Review
Interpretation 2163
Tier 1
BRAF
Variants
BRAF K601E
BRAF codon(s) 601 any
Primary Sites
Unknown
Tumor Types
Melanoma
Interpretation
Drug: Trametinib
Citations
Kim KB, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31(4):482-9
Bowyer SE, et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res 2014;24(5):504-8
Dahlman KB, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012;2(9):791-7
Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107-14
Last updated: 2018-04-06 15:09:24 UTC
PMKB Bot
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity